Nebius Group N.V.

NBIS

Held by 1 specialist biotech fund

Share on X

Fund Holdings

Eventide Asset Management

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

Eventide Asset ManagementNEWFeb 13, 2026

Shares: 18,491Value: $1.5M

**Signal Note: Eventide Values-Based Biotech Entry into Nebius** Eventide's $1.5M initiation of NBIS appears misaligned with typical biotech thesis—Nebius is a cloud/AI infrastructure play, not a drug developer, suggesting the values-based investor may be positioning for AI-driven biotech applications or computational biology infrastructure. This entry lacks the traditional clinical catalyst or indication-specific rationale common to Eventide's core biotech positions, warranting clarification on whether this represents portfolio diversification or a thematic bet on AI-enabled drug discovery platforms.

More NBIS Analysis

Insider buy/sell details with names, titles, and amounts
AI-generated context for every signal

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CPRT1 fund DECK1 fund LITE1 fund NTAP1 fund GPI1 fund IMMX1 fund PI1 fund UNP1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief: